Second, we observed that CLL patients with high soluble CXCL-13 and galectin-9 levels had advanced clinical stages, poor prognosis, 17p del, short PFS, short TTT, and therapy resistance. The gene discussed is CXCL13; the disease is B-cell chronic lymphocytic leukemia.